A Trial to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.0 mg/mL
Latest Information Update: 05 Jun 2020
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Overweight
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 02 Jun 2020 Status changed from active, no longer recruiting to completed.
- 30 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Feb 2020 Status changed from not yet recruiting to recruiting.